Sonoma pharmaceuticals reports third quarter 2023 financial results

Cash burn of $717,000 for the quarter ended december 31, 2022, 68% less than prior quarter cash burn of $2,235,000 revenues for three and nine months ended december 31, 2022 essentially flat with strong performance in international sales european revenues increased 51% for the quarter and 29% for the nine months ended december 31, 2022, compared to the same periods prior year boulder, co / accesswire / february 14, 2023 / sonoma pharmaceuticals, inc. (nasdaq:snoa),a global healthcare leader developing and producing stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced financial results for its third fiscal quarter and nine months ended december 31, 2022. "our revenues remain strong despite overall economic trends such as inflation, and reduced consumer spending.
SNOA Ratings Summary
SNOA Quant Ranking